Moore RD - Search Results

1

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J Jr, Moore RD, Gange SJ, Siliciano RF. Siliciano JD, et al. Among authors: moore rd. J Infect Dis. 2007 Mar 15;195(6):833-6. doi: 10.1086/511823. Epub 2007 Jan 30. J Infect Dis. 2007. PMID: 17299713

2

Anemia in HIV-infected patients receiving highly active antiretroviral therapy.

Moore RD, Forney D. Moore RD, et al. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):54-7. doi: 10.1097/00042560-200201010-00007. J Acquir Immune Defic Syndr. 2002. PMID: 11782590

3

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Sulkowski MS, et al. Among authors: moore rd. JAMA. 2002 Jul 10;288(2):199-206. doi: 10.1001/jama.288.2.199. JAMA. 2002. PMID: 12095384

4

Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort.

Perez JL, Moore RD. Perez JL, et al. Among authors: moore rd. Clin Infect Dis. 2003 Jan 15;36(2):212-8. doi: 10.1086/345669. Epub 2003 Jan 6. Clin Infect Dis. 2003. PMID: 12522755

5

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.

Sterling TR, Chaisson RE, Moore RD. Sterling TR, et al. Among authors: moore rd. Clin Infect Dis. 2003 Mar 15;36(6):812-5. doi: 10.1086/367934. Epub 2003 Feb 27. Clin Infect Dis. 2003. PMID: 12627368

6

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Sethi AK, et al. Among authors: moore rd. Clin Infect Dis. 2003 Oct 15;37(8):1112-8. doi: 10.1086/378301. Epub 2003 Sep 19. Clin Infect Dis. 2003. PMID: 14523777

7

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

8

Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.

Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Lucas GM, et al. Among authors: moore rd. AIDS. 2004 Feb 20;18(3):541-6. doi: 10.1097/00002030-200402200-00022. AIDS. 2004. PMID: 15090808

9

Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study.

Lucas GM, Weidle PJ, Hader S, Moore RD. Lucas GM, et al. Among authors: moore rd. Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S409-13. doi: 10.1086/421405. Clin Infect Dis. 2004. PMID: 15156431 Clinical Trial.

10

Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.

Lucas GM, Gallant JE, Moore RD. Lucas GM, et al. Among authors: moore rd. AIDS. 2004 Jul 23;18(11):1539-48. doi: 10.1097/01.aids.0000131339.68666.1a. AIDS. 2004. PMID: 15238772

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

903 results

Search Page